1. Several patents exist related to stem cell research, including patents covering methods of culturing primordial germ cells and pluripotent embryonic stem cells.
2. The Wisconsin Alumni Research Foundation (WARF) owns patents related to human embryonic stem cells that are reportedly available for licensing.
3. WARF is asking for $100,000 upfront fee and $25,000 annual fee to license their patents for commercial use related to stem cell therapies.
El documento proporciona información básica sobre Manuel Antonio Andujar, incluyendo su número de cédula, fecha y lugar de nacimiento en 1952 en Santo Domingo, su estado civil de casado, nacionalidad dominicana, educación hasta 8vo grado, y experiencia laboral como mecánico supervisor con referencia en el periódico Hoy.
Este documento brinda algunas reglas ortográficas para usar correctamente las letras 'b' y 'v'. Explica que la 'b' es una consonante bilabial sonora, mientras que la 'v' es velar sonora. Luego enumera ejemplos de palabras que se escriben con 'b', como aquellas que comienzan con 'bu-', 'bur-', 'bis-', así como verbos como 'deber', 'caber', 'haber' y 'saber'.
The document discusses stem cell patentability in Europe. It notes that pluripotent stem cells can form all tissues but not extra-embryonic tissue, while totipotent stem cells can form a whole organism. The European Patent Convention prohibits patents on inventions that exploit human embryos. However, stem cell patents are allowed if they do not require human embryo destruction or use embryos for commercial purposes. Recent court cases have further clarified these guidelines around patenting stem cells and cell lines derived from embryos. National laws on stem cell patents vary and ethical views continue evolving over time.
Focus on Pharma: Creating, Protecting & Enforcing High-Value IP AssetsSterneKessler
A two-day conference held by Sterne, Kessler, Goldstein & Fox P.L.L.C., which focused on on recent trends in substantive case law, their impact on patent prosecution and examination, and implications regarding the enforcement of patents in the pharmaceutical and biopharmaceutical industry.
This document summarizes a USPTO Bio/Chem/Pharma Customer Partnership meeting in September 2006. About 100 people attended in person and 40 attended virtually. Key topics discussed included recent changes to restriction practice, data on restriction petition outcomes, new accelerated examination rules, the examination of bioinformatics cases, and upcoming proposed rule changes regarding claims, continuations, IDS practice and Markush claims. Speakers from various technology centers and art units provided updates in their areas. Attendees engaged in discussion and questions.
SKGF_Advisory_US Design Patents Strengthened by Recent Federal Circuit Ruling...SterneKessler
The Federal Circuit issued a decision strengthening US design patents. It threw out the "point of novelty" test for infringement and returned to a test of whether the accused design is "substantially the same as" or a "colorable imitation" of the patented design. This simplifies the test for infringement and shifts the burden of comparing the patented design to prior art to the accused infringer. The decision also cautions against describing a design patent's drawings with words, which could unduly emphasize particular features over the design as a whole. This ruling should reduce design patent litigation costs for patent holders and make summary judgment of infringement more likely.
SKGF_Advisory_Two Questions Every Wind Energy Company Should Ask Itself_2009SterneKessler
Before bringing a new wind turbine product to market, companies should ask two important questions: 1) Does someone hold a patent that could block sales of the product? and 2) Can the company's patents block competitors from selling similar products? To answer the first question, companies should thoroughly review their product and related patents to ensure freedom to operate without infringement. They should also consider pending patent applications that could issue as enforceable patents. To answer the second question, companies should seek patents on novel and non-obvious aspects of their product to create roadblocks for competitors. Conducting this analysis can help companies avoid infringement liability and protect their market position.
El documento proporciona información básica sobre Manuel Antonio Andujar, incluyendo su número de cédula, fecha y lugar de nacimiento en 1952 en Santo Domingo, su estado civil de casado, nacionalidad dominicana, educación hasta 8vo grado, y experiencia laboral como mecánico supervisor con referencia en el periódico Hoy.
Este documento brinda algunas reglas ortográficas para usar correctamente las letras 'b' y 'v'. Explica que la 'b' es una consonante bilabial sonora, mientras que la 'v' es velar sonora. Luego enumera ejemplos de palabras que se escriben con 'b', como aquellas que comienzan con 'bu-', 'bur-', 'bis-', así como verbos como 'deber', 'caber', 'haber' y 'saber'.
The document discusses stem cell patentability in Europe. It notes that pluripotent stem cells can form all tissues but not extra-embryonic tissue, while totipotent stem cells can form a whole organism. The European Patent Convention prohibits patents on inventions that exploit human embryos. However, stem cell patents are allowed if they do not require human embryo destruction or use embryos for commercial purposes. Recent court cases have further clarified these guidelines around patenting stem cells and cell lines derived from embryos. National laws on stem cell patents vary and ethical views continue evolving over time.
Focus on Pharma: Creating, Protecting & Enforcing High-Value IP AssetsSterneKessler
A two-day conference held by Sterne, Kessler, Goldstein & Fox P.L.L.C., which focused on on recent trends in substantive case law, their impact on patent prosecution and examination, and implications regarding the enforcement of patents in the pharmaceutical and biopharmaceutical industry.
This document summarizes a USPTO Bio/Chem/Pharma Customer Partnership meeting in September 2006. About 100 people attended in person and 40 attended virtually. Key topics discussed included recent changes to restriction practice, data on restriction petition outcomes, new accelerated examination rules, the examination of bioinformatics cases, and upcoming proposed rule changes regarding claims, continuations, IDS practice and Markush claims. Speakers from various technology centers and art units provided updates in their areas. Attendees engaged in discussion and questions.
SKGF_Advisory_US Design Patents Strengthened by Recent Federal Circuit Ruling...SterneKessler
The Federal Circuit issued a decision strengthening US design patents. It threw out the "point of novelty" test for infringement and returned to a test of whether the accused design is "substantially the same as" or a "colorable imitation" of the patented design. This simplifies the test for infringement and shifts the burden of comparing the patented design to prior art to the accused infringer. The decision also cautions against describing a design patent's drawings with words, which could unduly emphasize particular features over the design as a whole. This ruling should reduce design patent litigation costs for patent holders and make summary judgment of infringement more likely.
SKGF_Advisory_Two Questions Every Wind Energy Company Should Ask Itself_2009SterneKessler
Before bringing a new wind turbine product to market, companies should ask two important questions: 1) Does someone hold a patent that could block sales of the product? and 2) Can the company's patents block competitors from selling similar products? To answer the first question, companies should thoroughly review their product and related patents to ensure freedom to operate without infringement. They should also consider pending patent applications that could issue as enforceable patents. To answer the second question, companies should seek patents on novel and non-obvious aspects of their product to create roadblocks for competitors. Conducting this analysis can help companies avoid infringement liability and protect their market position.
The document summarizes the February 24, 2006 hearing between NTP, RIM, and the US government over NTP's patent infringement claims against RIM regarding Blackberry technology. It outlines two possible scenarios for how the judge, James R. Spencer, may rule on damages and an injunction. The first scenario has Judge Spencer siding more with NTP, awarding them full damages and ultimately blocking Blackberry services. The second scenario favors RIM more, with lower initial damages and no service interruption. The authors believe the first outcome is more likely.
SKGF_Advisory_Strategies for Life Under the New USPTO Rules on Continuation a...SterneKessler
The document summarizes new rules from the USPTO regarding continuation and claims practice that take effect on November 1, 2007. Key points of the new rules include: limiting the number of claims to 5 independent and 25 total without an examination support document; limiting continuations and RCEs to two "as of right" per family; requiring commonly owned applications to be identified. The document provides strategies for dealing with the new rules such as using suggested restriction requirements and filing continuations serially after a parent is allowed.
SKGF_Advisory_SKGF Forms Stem Cell Task Force Advisory_2005SterneKessler
A law firm formed a Stem Cell Task Force in 2004 to stay up-to-date on legal and policy developments regarding stem cells and inform clients. The task force has published three pieces on stem cell patenting, including one on California's Proposition 71 and the stem cell patent landscape. Their latest publication discusses whether patent pools could help resolve stem cell patent issues.
SKGF_Advisory_Reexamination Practice with Concurrent District Court or USITC ...SterneKessler
This document discusses the interplay between patent litigation in federal courts or the International Trade Commission and concurrent reexamination proceedings involving the same patent before the US Patent and Trademark Office. It notes that these "parallel universes" operate with separate rules, standards, procedures, timelines and results. The increased use of reexamination as an alternative venue to challenge patent validity when district court litigation has been initiated is discussed. Key factors driving this include the USPTO's focus on making reexamination more efficient and changes in the legal landscape regarding patent validity and obviousness standards from Supreme Court cases. The impact of potential reexaminations is now commonly considered in nearly all patent litigation.
SKGF_Advisory_Real World Impacts of Reexamination Practice and Procedure_2008SterneKessler
This document discusses issues related to patent reexamination procedures and their impact on patent owners. It provides background on ex parte and inter partes reexamination procedures. It then discusses concerns about the low standard for instituting reexaminations, the impact of reexaminations on capital markets, and identifying the real party in interest in inter partes reexaminations. It proposes solutions such as increasing the standard for reexaminations involving previously litigated patents or previous reexams and keeping reexamination proceedings confidential until a final office action.
SKGF_Advisory_Preparing and Prosecuting a Patent that Holds up in Litigation_...SterneKessler
This document provides guidance on preparing and prosecuting a patent application to obtain a patent that will withstand litigation. It discusses considerations prior to filing such as conducting a prior art search, carefully drafting claims to avoid obvious errors or unnecessary limitations, and ascertaining inventorship. During prosecution, it recommends fully complying with the duty of disclosure and using interviews and narrowing amendments strategically. Post-issuance, it suggests using certificates of correction, reissue applications, and reexamination where needed to strengthen the patent. The overall goal is to obtain a valid, enforceable patent by addressing weaknesses before they can be exploited in litigation.
SKGF_Advisory_Living in a Post KSR World_2007SterneKessler
This document provides an overview of how the Supreme Court's 2007 decision in KSR International Co. v. Teleflex Inc. has impacted obviousness determinations at the Federal Circuit, district courts, and USPTO. Since KSR, the Federal Circuit has found inventions obvious in 6 out of 9 precedential decisions. While some language in opinions remains similar to pre-KSR cases, the standard for determining obviousness is less rigid, with motivation or reason to combine references no longer required to be explicit. District courts are more readily granting summary judgment of obviousness. The USPTO has also been impacted but specifics are still emerging.
SKGF_Advisory_Federal Circuit Issues Decision in TAFAS v. Doll_2009SterneKessler
The United States Court of Appeals for the Federal Circuit issued a decision in Tafas v. Doll regarding USPTO rules on claims, continuation applications, and Requests for Continuation Examination (RCEs). While the Federal Circuit found the rules to be procedural and within the USPTO's authority, it determined the rule limiting continuation filings to two was inconsistent with statute. The validity of the rules limiting claims and RCEs was not affirmed and was remanded for further consideration. The opinion was issued by a three-judge panel with disagreement on some aspects. The parties can request rehearing by the full panel of judges.
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005SterneKessler
Stem cell research faces challenges due to numerous existing and pending patents covering related technologies. A patent pool is proposed to consolidate these patents into a single license to streamline access for researchers and developers. A patent pool would integrate complementary patents and reduce costs by avoiding multiple licensing agreements. However, any patent pool must be carefully designed to avoid anti-competitive behaviors like restricting innovation. If properly structured, a stem cell patent pool could enable continued progress while respecting patent holders' rights.
SKGF_Advisory_Nanotechnology Practice News_2005SterneKessler
The law firm Sterne, Kessler, Goldstein & Fox provides an update on its growing nanotechnology practice. It has hired three new Ph.D. scientists - Dr. Barron, Dr. Lukas, and Dr. Tuminaro - to strengthen its technical expertise in areas like tissue engineering, protein microarrays, nanoporous materials, and solid state physics. It has also analyzed nanotechnology patent prosecution histories and plans to present preliminary results of its comprehensive study of all nanotube patents issued in 2004 at the 2005 NSTI conference.
SKGF_Presentation_What You Need To Know About The Proposed USPTO Rule Changes...SterneKessler
The document discusses proposed rule changes and initiatives at the USPTO aimed at addressing issues related to patent application pendency, quality, and backlog. Specifically, it outlines proposed rules that would limit continuing applications and requests for continued examination by requiring additional showings for second or subsequent filings. It also discusses a proposed rule change to allow examiners to focus initial examination on representative claims designated by the applicant and defer examination of non-designated claims. The document provides examples and recommendations for practitioners regarding the proposed changes.
SKGF_Presentation_The Supreme Courts Renewed Interest In IP_April 2007SterneKessler
The Supreme Court has recently taken a renewed interest in intellectual property cases, reviewing and reversing several Federal Circuit rulings over the past decade. This suggests the Supreme Court is unhappy with the Federal Circuit's handling of patent law and prefers flexibility over bright-line rules. There are indications the Supreme Court views IP law as more important today than in the past and wants to ensure consistency with how other types of cases are handled. The talk examines this growing tension between the two courts with implications for how patent cases may be decided going forward.
This document discusses intellectual property considerations for nanotechnology. It defines intellectual property and outlines patent, trademark, copyright and trade secret protections. It focuses on patent rights, describing the requirements to obtain a patent, the patent application process, and key stages from conception of an idea to patent issuance. Challenges in nanotechnology such as incomplete ideas and newness of the field are addressed. The importance of documentation, education of attorneys, broad claims, and leveraging the patent process are emphasized for obtaining strong nanotechnology patent rights.
The document summarizes the results of a 2004 study of 206 US patents issued that year containing "nanotube" in the claims, finding that the patents covered a wide range of technologies, took an average of 28 months to issue, and examinations showed relatively high allowance rates, suggesting less rigorous review by the Patent Office.
SKGF_Presentation_Nanotechnology IP Licensing Think Big, But Keep Your Feet O...SterneKessler
This document summarizes a presentation on nanotechnology intellectual property licensing. It discusses how the USPTO is handling nanotechnology patents, noting the disruptive and pervasive nature of nanotechnology. It outlines challenges in obtaining patent protection for nanotechnology inventions due to issues like enablement, inherency, and breadth of claims. The document also discusses considerations for nanotechnology licensing agreements, including ownership issues, license income structures, and performance requirements.
Marvin C. Guthrie presented at the International Engineering Consortium NanoEngineering World Forum on June 23, 2003. The presentation discussed intellectual property strategies for transferring technology depending on whether you are from academia, industry or venture capital. It also covered issues like funding source encumbrances, acquiring technology through assignments and licenses, exclusivity in licenses, and considerations in licensing agreements like maintenance of IP and enforcement.
This document summarizes a presentation on nanotechnology perspectives and intellectual property given at Duke University School of Law in 2004. It begins with an overview of nanotechnology basics including definitions and applications in various fields such as life sciences, electronics, and energy. It then discusses the nanotechnology business environment and examines the role of intellectual property in nanotechnology, focusing on patent preparation, prosecution, licensing, and technology transfer considerations. The presentation aims to provide context around the state of nanotechnology and intellectual property at that time.
SKGF_Presentation_USPTO Patent Examination Reform and Proposed Rule Changes-2006SterneKessler
The document discusses proposed rule changes and initiatives at the US Patent and Trademark Office (USPTO) to address issues with patent examination including pendency, quality, and keeping up with growth. Specifically, it notes the USPTO has hired more examiners, formed a central re-examination unit, extended second-layer review office wide, collected more software prior art, changed the patent academy, instituted examiner re-certification, allowed telecommuting, reduced allowance rates, and reduced error rates in patent allowance. It also shows data on pendency and inventory by technology area.
The document discusses the past, present, and future of patenting antibodies. It summarizes key court cases around patenting antibodies and the technologies involved. Additionally, it addresses current issues regarding freedom-to-operate for antibody technologies and explores how antibody patenting may evolve in the future as the technology continues to advance. Therapeutic antibodies have become a major market but also face increasing competition, so maintaining a strong patent portfolio is important to protect investments and maximize value.
SKGF_Presentation_Nanotechnology Patents: What Can Be Learned?_2005SterneKessler
The document summarizes ten important nanotechnology patents and discusses some key issues regarding nanotechnology patents. It lists the top ten nanotechnology patents by patent number, title, and issue date. It then analyzes issues like size considerations in examination, confusing nomenclature, rigorous examination requiring amendments and cancellations, and the average 26 month pendency period for Class 977 patents.
HCL Notes and Domino License Cost Reduction in the World of DLAUpanagenda
Webinar Recording: https://www.panagenda.com/webinars/hcl-notes-and-domino-license-cost-reduction-in-the-world-of-dlau/
The introduction of DLAU and the CCB & CCX licensing model caused quite a stir in the HCL community. As a Notes and Domino customer, you may have faced challenges with unexpected user counts and license costs. You probably have questions on how this new licensing approach works and how to benefit from it. Most importantly, you likely have budget constraints and want to save money where possible. Don’t worry, we can help with all of this!
We’ll show you how to fix common misconfigurations that cause higher-than-expected user counts, and how to identify accounts which you can deactivate to save money. There are also frequent patterns that can cause unnecessary cost, like using a person document instead of a mail-in for shared mailboxes. We’ll provide examples and solutions for those as well. And naturally we’ll explain the new licensing model.
Join HCL Ambassador Marc Thomas in this webinar with a special guest appearance from Franz Walder. It will give you the tools and know-how to stay on top of what is going on with Domino licensing. You will be able lower your cost through an optimized configuration and keep it low going forward.
These topics will be covered
- Reducing license cost by finding and fixing misconfigurations and superfluous accounts
- How do CCB and CCX licenses really work?
- Understanding the DLAU tool and how to best utilize it
- Tips for common problem areas, like team mailboxes, functional/test users, etc
- Practical examples and best practices to implement right away
The document summarizes the February 24, 2006 hearing between NTP, RIM, and the US government over NTP's patent infringement claims against RIM regarding Blackberry technology. It outlines two possible scenarios for how the judge, James R. Spencer, may rule on damages and an injunction. The first scenario has Judge Spencer siding more with NTP, awarding them full damages and ultimately blocking Blackberry services. The second scenario favors RIM more, with lower initial damages and no service interruption. The authors believe the first outcome is more likely.
SKGF_Advisory_Strategies for Life Under the New USPTO Rules on Continuation a...SterneKessler
The document summarizes new rules from the USPTO regarding continuation and claims practice that take effect on November 1, 2007. Key points of the new rules include: limiting the number of claims to 5 independent and 25 total without an examination support document; limiting continuations and RCEs to two "as of right" per family; requiring commonly owned applications to be identified. The document provides strategies for dealing with the new rules such as using suggested restriction requirements and filing continuations serially after a parent is allowed.
SKGF_Advisory_SKGF Forms Stem Cell Task Force Advisory_2005SterneKessler
A law firm formed a Stem Cell Task Force in 2004 to stay up-to-date on legal and policy developments regarding stem cells and inform clients. The task force has published three pieces on stem cell patenting, including one on California's Proposition 71 and the stem cell patent landscape. Their latest publication discusses whether patent pools could help resolve stem cell patent issues.
SKGF_Advisory_Reexamination Practice with Concurrent District Court or USITC ...SterneKessler
This document discusses the interplay between patent litigation in federal courts or the International Trade Commission and concurrent reexamination proceedings involving the same patent before the US Patent and Trademark Office. It notes that these "parallel universes" operate with separate rules, standards, procedures, timelines and results. The increased use of reexamination as an alternative venue to challenge patent validity when district court litigation has been initiated is discussed. Key factors driving this include the USPTO's focus on making reexamination more efficient and changes in the legal landscape regarding patent validity and obviousness standards from Supreme Court cases. The impact of potential reexaminations is now commonly considered in nearly all patent litigation.
SKGF_Advisory_Real World Impacts of Reexamination Practice and Procedure_2008SterneKessler
This document discusses issues related to patent reexamination procedures and their impact on patent owners. It provides background on ex parte and inter partes reexamination procedures. It then discusses concerns about the low standard for instituting reexaminations, the impact of reexaminations on capital markets, and identifying the real party in interest in inter partes reexaminations. It proposes solutions such as increasing the standard for reexaminations involving previously litigated patents or previous reexams and keeping reexamination proceedings confidential until a final office action.
SKGF_Advisory_Preparing and Prosecuting a Patent that Holds up in Litigation_...SterneKessler
This document provides guidance on preparing and prosecuting a patent application to obtain a patent that will withstand litigation. It discusses considerations prior to filing such as conducting a prior art search, carefully drafting claims to avoid obvious errors or unnecessary limitations, and ascertaining inventorship. During prosecution, it recommends fully complying with the duty of disclosure and using interviews and narrowing amendments strategically. Post-issuance, it suggests using certificates of correction, reissue applications, and reexamination where needed to strengthen the patent. The overall goal is to obtain a valid, enforceable patent by addressing weaknesses before they can be exploited in litigation.
SKGF_Advisory_Living in a Post KSR World_2007SterneKessler
This document provides an overview of how the Supreme Court's 2007 decision in KSR International Co. v. Teleflex Inc. has impacted obviousness determinations at the Federal Circuit, district courts, and USPTO. Since KSR, the Federal Circuit has found inventions obvious in 6 out of 9 precedential decisions. While some language in opinions remains similar to pre-KSR cases, the standard for determining obviousness is less rigid, with motivation or reason to combine references no longer required to be explicit. District courts are more readily granting summary judgment of obviousness. The USPTO has also been impacted but specifics are still emerging.
SKGF_Advisory_Federal Circuit Issues Decision in TAFAS v. Doll_2009SterneKessler
The United States Court of Appeals for the Federal Circuit issued a decision in Tafas v. Doll regarding USPTO rules on claims, continuation applications, and Requests for Continuation Examination (RCEs). While the Federal Circuit found the rules to be procedural and within the USPTO's authority, it determined the rule limiting continuation filings to two was inconsistent with statute. The validity of the rules limiting claims and RCEs was not affirmed and was remanded for further consideration. The opinion was issued by a three-judge panel with disagreement on some aspects. The parties can request rehearing by the full panel of judges.
SKGF_Advisory_Stem Cells-Patent Pools to the Rescue_2005SterneKessler
Stem cell research faces challenges due to numerous existing and pending patents covering related technologies. A patent pool is proposed to consolidate these patents into a single license to streamline access for researchers and developers. A patent pool would integrate complementary patents and reduce costs by avoiding multiple licensing agreements. However, any patent pool must be carefully designed to avoid anti-competitive behaviors like restricting innovation. If properly structured, a stem cell patent pool could enable continued progress while respecting patent holders' rights.
SKGF_Advisory_Nanotechnology Practice News_2005SterneKessler
The law firm Sterne, Kessler, Goldstein & Fox provides an update on its growing nanotechnology practice. It has hired three new Ph.D. scientists - Dr. Barron, Dr. Lukas, and Dr. Tuminaro - to strengthen its technical expertise in areas like tissue engineering, protein microarrays, nanoporous materials, and solid state physics. It has also analyzed nanotechnology patent prosecution histories and plans to present preliminary results of its comprehensive study of all nanotube patents issued in 2004 at the 2005 NSTI conference.
SKGF_Presentation_What You Need To Know About The Proposed USPTO Rule Changes...SterneKessler
The document discusses proposed rule changes and initiatives at the USPTO aimed at addressing issues related to patent application pendency, quality, and backlog. Specifically, it outlines proposed rules that would limit continuing applications and requests for continued examination by requiring additional showings for second or subsequent filings. It also discusses a proposed rule change to allow examiners to focus initial examination on representative claims designated by the applicant and defer examination of non-designated claims. The document provides examples and recommendations for practitioners regarding the proposed changes.
SKGF_Presentation_The Supreme Courts Renewed Interest In IP_April 2007SterneKessler
The Supreme Court has recently taken a renewed interest in intellectual property cases, reviewing and reversing several Federal Circuit rulings over the past decade. This suggests the Supreme Court is unhappy with the Federal Circuit's handling of patent law and prefers flexibility over bright-line rules. There are indications the Supreme Court views IP law as more important today than in the past and wants to ensure consistency with how other types of cases are handled. The talk examines this growing tension between the two courts with implications for how patent cases may be decided going forward.
This document discusses intellectual property considerations for nanotechnology. It defines intellectual property and outlines patent, trademark, copyright and trade secret protections. It focuses on patent rights, describing the requirements to obtain a patent, the patent application process, and key stages from conception of an idea to patent issuance. Challenges in nanotechnology such as incomplete ideas and newness of the field are addressed. The importance of documentation, education of attorneys, broad claims, and leveraging the patent process are emphasized for obtaining strong nanotechnology patent rights.
The document summarizes the results of a 2004 study of 206 US patents issued that year containing "nanotube" in the claims, finding that the patents covered a wide range of technologies, took an average of 28 months to issue, and examinations showed relatively high allowance rates, suggesting less rigorous review by the Patent Office.
SKGF_Presentation_Nanotechnology IP Licensing Think Big, But Keep Your Feet O...SterneKessler
This document summarizes a presentation on nanotechnology intellectual property licensing. It discusses how the USPTO is handling nanotechnology patents, noting the disruptive and pervasive nature of nanotechnology. It outlines challenges in obtaining patent protection for nanotechnology inventions due to issues like enablement, inherency, and breadth of claims. The document also discusses considerations for nanotechnology licensing agreements, including ownership issues, license income structures, and performance requirements.
Marvin C. Guthrie presented at the International Engineering Consortium NanoEngineering World Forum on June 23, 2003. The presentation discussed intellectual property strategies for transferring technology depending on whether you are from academia, industry or venture capital. It also covered issues like funding source encumbrances, acquiring technology through assignments and licenses, exclusivity in licenses, and considerations in licensing agreements like maintenance of IP and enforcement.
This document summarizes a presentation on nanotechnology perspectives and intellectual property given at Duke University School of Law in 2004. It begins with an overview of nanotechnology basics including definitions and applications in various fields such as life sciences, electronics, and energy. It then discusses the nanotechnology business environment and examines the role of intellectual property in nanotechnology, focusing on patent preparation, prosecution, licensing, and technology transfer considerations. The presentation aims to provide context around the state of nanotechnology and intellectual property at that time.
SKGF_Presentation_USPTO Patent Examination Reform and Proposed Rule Changes-2006SterneKessler
The document discusses proposed rule changes and initiatives at the US Patent and Trademark Office (USPTO) to address issues with patent examination including pendency, quality, and keeping up with growth. Specifically, it notes the USPTO has hired more examiners, formed a central re-examination unit, extended second-layer review office wide, collected more software prior art, changed the patent academy, instituted examiner re-certification, allowed telecommuting, reduced allowance rates, and reduced error rates in patent allowance. It also shows data on pendency and inventory by technology area.
The document discusses the past, present, and future of patenting antibodies. It summarizes key court cases around patenting antibodies and the technologies involved. Additionally, it addresses current issues regarding freedom-to-operate for antibody technologies and explores how antibody patenting may evolve in the future as the technology continues to advance. Therapeutic antibodies have become a major market but also face increasing competition, so maintaining a strong patent portfolio is important to protect investments and maximize value.
SKGF_Presentation_Nanotechnology Patents: What Can Be Learned?_2005SterneKessler
The document summarizes ten important nanotechnology patents and discusses some key issues regarding nanotechnology patents. It lists the top ten nanotechnology patents by patent number, title, and issue date. It then analyzes issues like size considerations in examination, confusing nomenclature, rigorous examination requiring amendments and cancellations, and the average 26 month pendency period for Class 977 patents.
HCL Notes and Domino License Cost Reduction in the World of DLAUpanagenda
Webinar Recording: https://www.panagenda.com/webinars/hcl-notes-and-domino-license-cost-reduction-in-the-world-of-dlau/
The introduction of DLAU and the CCB & CCX licensing model caused quite a stir in the HCL community. As a Notes and Domino customer, you may have faced challenges with unexpected user counts and license costs. You probably have questions on how this new licensing approach works and how to benefit from it. Most importantly, you likely have budget constraints and want to save money where possible. Don’t worry, we can help with all of this!
We’ll show you how to fix common misconfigurations that cause higher-than-expected user counts, and how to identify accounts which you can deactivate to save money. There are also frequent patterns that can cause unnecessary cost, like using a person document instead of a mail-in for shared mailboxes. We’ll provide examples and solutions for those as well. And naturally we’ll explain the new licensing model.
Join HCL Ambassador Marc Thomas in this webinar with a special guest appearance from Franz Walder. It will give you the tools and know-how to stay on top of what is going on with Domino licensing. You will be able lower your cost through an optimized configuration and keep it low going forward.
These topics will be covered
- Reducing license cost by finding and fixing misconfigurations and superfluous accounts
- How do CCB and CCX licenses really work?
- Understanding the DLAU tool and how to best utilize it
- Tips for common problem areas, like team mailboxes, functional/test users, etc
- Practical examples and best practices to implement right away
Threats to mobile devices are more prevalent and increasing in scope and complexity. Users of mobile devices desire to take full advantage of the features
available on those devices, but many of the features provide convenience and capability but sacrifice security. This best practices guide outlines steps the users can take to better protect personal devices and information.
Fueling AI with Great Data with Airbyte WebinarZilliz
This talk will focus on how to collect data from a variety of sources, leveraging this data for RAG and other GenAI use cases, and finally charting your course to productionalization.
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slackshyamraj55
Discover the seamless integration of RPA (Robotic Process Automation), COMPOSER, and APM with AWS IDP enhanced with Slack notifications. Explore how these technologies converge to streamline workflows, optimize performance, and ensure secure access, all while leveraging the power of AWS IDP and real-time communication via Slack notifications.
UiPath Test Automation using UiPath Test Suite series, part 6DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 6. In this session, we will cover Test Automation with generative AI and Open AI.
UiPath Test Automation with generative AI and Open AI webinar offers an in-depth exploration of leveraging cutting-edge technologies for test automation within the UiPath platform. Attendees will delve into the integration of generative AI, a test automation solution, with Open AI advanced natural language processing capabilities.
Throughout the session, participants will discover how this synergy empowers testers to automate repetitive tasks, enhance testing accuracy, and expedite the software testing life cycle. Topics covered include the seamless integration process, practical use cases, and the benefits of harnessing AI-driven automation for UiPath testing initiatives. By attending this webinar, testers, and automation professionals can gain valuable insights into harnessing the power of AI to optimize their test automation workflows within the UiPath ecosystem, ultimately driving efficiency and quality in software development processes.
What will you get from this session?
1. Insights into integrating generative AI.
2. Understanding how this integration enhances test automation within the UiPath platform
3. Practical demonstrations
4. Exploration of real-world use cases illustrating the benefits of AI-driven test automation for UiPath
Topics covered:
What is generative AI
Test Automation with generative AI and Open AI.
UiPath integration with generative AI
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?Speck&Tech
ABSTRACT: A prima vista, un mattoncino Lego e la backdoor XZ potrebbero avere in comune il fatto di essere entrambi blocchi di costruzione, o dipendenze di progetti creativi e software. La realtà è che un mattoncino Lego e il caso della backdoor XZ hanno molto di più di tutto ciò in comune.
Partecipate alla presentazione per immergervi in una storia di interoperabilità, standard e formati aperti, per poi discutere del ruolo importante che i contributori hanno in una comunità open source sostenibile.
BIO: Sostenitrice del software libero e dei formati standard e aperti. È stata un membro attivo dei progetti Fedora e openSUSE e ha co-fondato l'Associazione LibreItalia dove è stata coinvolta in diversi eventi, migrazioni e formazione relativi a LibreOffice. In precedenza ha lavorato a migrazioni e corsi di formazione su LibreOffice per diverse amministrazioni pubbliche e privati. Da gennaio 2020 lavora in SUSE come Software Release Engineer per Uyuni e SUSE Manager e quando non segue la sua passione per i computer e per Geeko coltiva la sua curiosità per l'astronomia (da cui deriva il suo nickname deneb_alpha).
Ocean lotus Threat actors project by John Sitima 2024 (1).pptxSitimaJohn
Ocean Lotus cyber threat actors represent a sophisticated, persistent, and politically motivated group that poses a significant risk to organizations and individuals in the Southeast Asian region. Their continuous evolution and adaptability underscore the need for robust cybersecurity measures and international cooperation to identify and mitigate the threats posed by such advanced persistent threat groups.
TrustArc Webinar - 2024 Global Privacy SurveyTrustArc
How does your privacy program stack up against your peers? What challenges are privacy teams tackling and prioritizing in 2024?
In the fifth annual Global Privacy Benchmarks Survey, we asked over 1,800 global privacy professionals and business executives to share their perspectives on the current state of privacy inside and outside of their organizations. This year’s report focused on emerging areas of importance for privacy and compliance professionals, including considerations and implications of Artificial Intelligence (AI) technologies, building brand trust, and different approaches for achieving higher privacy competence scores.
See how organizational priorities and strategic approaches to data security and privacy are evolving around the globe.
This webinar will review:
- The top 10 privacy insights from the fifth annual Global Privacy Benchmarks Survey
- The top challenges for privacy leaders, practitioners, and organizations in 2024
- Key themes to consider in developing and maintaining your privacy program
Best 20 SEO Techniques To Improve Website Visibility In SERPPixlogix Infotech
Boost your website's visibility with proven SEO techniques! Our latest blog dives into essential strategies to enhance your online presence, increase traffic, and rank higher on search engines. From keyword optimization to quality content creation, learn how to make your site stand out in the crowded digital landscape. Discover actionable tips and expert insights to elevate your SEO game.
Main news related to the CCS TSI 2023 (2023/1695)Jakub Marek
An English 🇬🇧 translation of a presentation to the speech I gave about the main changes brought by CCS TSI 2023 at the biggest Czech conference on Communications and signalling systems on Railways, which was held in Clarion Hotel Olomouc from 7th to 9th November 2023 (konferenceszt.cz). Attended by around 500 participants and 200 on-line followers.
The original Czech 🇨🇿 version of the presentation can be found here: https://www.slideshare.net/slideshow/hlavni-novinky-souvisejici-s-ccs-tsi-2023-2023-1695/269688092 .
The videorecording (in Czech) from the presentation is available here: https://youtu.be/WzjJWm4IyPk?si=SImb06tuXGb30BEH .
In the rapidly evolving landscape of technologies, XML continues to play a vital role in structuring, storing, and transporting data across diverse systems. The recent advancements in artificial intelligence (AI) present new methodologies for enhancing XML development workflows, introducing efficiency, automation, and intelligent capabilities. This presentation will outline the scope and perspective of utilizing AI in XML development. The potential benefits and the possible pitfalls will be highlighted, providing a balanced view of the subject.
We will explore the capabilities of AI in understanding XML markup languages and autonomously creating structured XML content. Additionally, we will examine the capacity of AI to enrich plain text with appropriate XML markup. Practical examples and methodological guidelines will be provided to elucidate how AI can be effectively prompted to interpret and generate accurate XML markup.
Further emphasis will be placed on the role of AI in developing XSLT, or schemas such as XSD and Schematron. We will address the techniques and strategies adopted to create prompts for generating code, explaining code, or refactoring the code, and the results achieved.
The discussion will extend to how AI can be used to transform XML content. In particular, the focus will be on the use of AI XPath extension functions in XSLT, Schematron, Schematron Quick Fixes, or for XML content refactoring.
The presentation aims to deliver a comprehensive overview of AI usage in XML development, providing attendees with the necessary knowledge to make informed decisions. Whether you’re at the early stages of adopting AI or considering integrating it in advanced XML development, this presentation will cover all levels of expertise.
By highlighting the potential advantages and challenges of integrating AI with XML development tools and languages, the presentation seeks to inspire thoughtful conversation around the future of XML development. We’ll not only delve into the technical aspects of AI-powered XML development but also discuss practical implications and possible future directions.
Webinar: Designing a schema for a Data WarehouseFederico Razzoli
Are you new to data warehouses (DWH)? Do you need to check whether your data warehouse follows the best practices for a good design? In both cases, this webinar is for you.
A data warehouse is a central relational database that contains all measurements about a business or an organisation. This data comes from a variety of heterogeneous data sources, which includes databases of any type that back the applications used by the company, data files exported by some applications, or APIs provided by internal or external services.
But designing a data warehouse correctly is a hard task, which requires gathering information about the business processes that need to be analysed in the first place. These processes must be translated into so-called star schemas, which means, denormalised databases where each table represents a dimension or facts.
We will discuss these topics:
- How to gather information about a business;
- Understanding dictionaries and how to identify business entities;
- Dimensions and facts;
- Setting a table granularity;
- Types of facts;
- Types of dimensions;
- Snowflakes and how to avoid them;
- Expanding existing dimensions and facts.
Driving Business Innovation: Latest Generative AI Advancements & Success StorySafe Software
Are you ready to revolutionize how you handle data? Join us for a webinar where we’ll bring you up to speed with the latest advancements in Generative AI technology and discover how leveraging FME with tools from giants like Google Gemini, Amazon, and Microsoft OpenAI can supercharge your workflow efficiency.
During the hour, we’ll take you through:
Guest Speaker Segment with Hannah Barrington: Dive into the world of dynamic real estate marketing with Hannah, the Marketing Manager at Workspace Group. Hear firsthand how their team generates engaging descriptions for thousands of office units by integrating diverse data sources—from PDF floorplans to web pages—using FME transformers, like OpenAIVisionConnector and AnthropicVisionConnector. This use case will show you how GenAI can streamline content creation for marketing across the board.
Ollama Use Case: Learn how Scenario Specialist Dmitri Bagh has utilized Ollama within FME to input data, create custom models, and enhance security protocols. This segment will include demos to illustrate the full capabilities of FME in AI-driven processes.
Custom AI Models: Discover how to leverage FME to build personalized AI models using your data. Whether it’s populating a model with local data for added security or integrating public AI tools, find out how FME facilitates a versatile and secure approach to AI.
We’ll wrap up with a live Q&A session where you can engage with our experts on your specific use cases, and learn more about optimizing your data workflows with AI.
This webinar is ideal for professionals seeking to harness the power of AI within their data management systems while ensuring high levels of customization and security. Whether you're a novice or an expert, gain actionable insights and strategies to elevate your data processes. Join us to see how FME and AI can revolutionize how you work with data!
Energy Efficient Video Encoding for Cloud and Edge Computing Instances
SKGF_Presentation_Stem Cells The Patent Landscape_2005
1. culturing a primordial germ cell in a composition comprising the same 4 Table. Tissue Specific Stem Cell Patents WARF patents are reportedly available for licensing
Stem Cells – Introduction
The passage of Proposition 71 in California has lead to the
expectation that the massive new funding for stem cell research will
factors. It might be possible to avoid infringing these patents if the
pluripotential embryonic stem cells are not prepared by culturing the cells in
the presence of the four factors. This patent will expire in 2014.
Cell Type
Adipose-derived stem cell
Breast epithelial stem cells
Patent
Number
6,777,231
5,814,511
Assignee
Regents of the University of California
Michigan State University
Reportedly,1 WARF is asking for a $100,000 up front fee and a $25,000
annual maintenance fee from companies that take out a commercial
license. Geron has secured from
WARF exclusive U.S. rights to
The Patent
lead to the discovery of many new therapeutic treatments, including Vanderbilt also owns related U.S. Application 08/813,829 (unpublished) and Endothelial stem cells 6,852,533 Cornell Research Foundation, Inc. develop therapeutics and diagnostics
treatment for neurodegenerative diseases and traumatic injuries. One Published Application 2004/0071672. Dorsal root ganglion progenitor cells 6,835,567 Signal Pharmaceuticals, Inc. from human embryonic stem cell-
might also expect many new patents protecting these discoveries. Hematopoietic progenitor cells; derived neural, cardiomyocyte and
However, stem cell research has been ongoing for more than a decade Geron Corporation owns U.S. Pat. 6,642,048 which claims a method of CD34–, CD7+, Lin–, Lin–, CD45RA+ 6,537,807 Duke University
pancreatic islet cells. Research rights
and many patent applications have been granted already, even though proliferating human blastocyst-derived pluripotent stem cells in substantially Hematopoietic stem cells; Thy-1+ 5,061,620 SyStemix, Inc.
Landscape Hematopoietic stem cells; Thy-1+, CD34+
have been offered to academic and
there are as yet no FDA approved treatments. The implications of undifferentiated form, comprising culturing the cells in a growth 5,750,397 SyStemix, Inc.
governmental researchers without
such patents on research and development of therapeutic treatments environment essentially free of feeder cells, but that contains an extracellular Hematopoietic stem cells;
CD34+, CD38–, HLA-DR+ 5,840,580 Becton Dickinson and Co. royalties or fees. However, WARF
must be considered. matrix and a conditioned medium produced by a method comprising (a) reportedly charges $5,000 each
Hematopoietic lymphoid and dendritic cells;
culturing the cells in a tissue culture medium to give a conditioned medium, CD34+, CD45RA+, CD10+; time its subsidiary, WiCell
In order to better understand the extent of patenting that has already and then (b) harvesting the conditioned medium, wherein the cells used to
Robert W. Esmond and occurred, we undertook a search of all U.S. patents that use the terms condition the medium are from a non-malignant mouse cell line
Hematopoietic dendritic cells;
CD34+, CD45RA+, CD10+,
Hematopoietic stem cells, c-kit–, Thy-1–
5,972,627
5,876,956
SyStemix, Inc.
Johns Hopkins University School of Medicine
Research Institute, supplies one of
its cell lines to an academic
“stem cell(s),” “progenitor cell(s),” “precursor cell(s),” “multipotent immortalized by genetic engineering or a non-malignant human cell line that
Robert A. Schwartzman cell(s),” “pluripotent cell(s),” or “totipotent cell(s)” in their claims. proliferates in culture for at least 60 days. Also claimed is a composition of Hematopoietic stem cells, CD34+
Hematopoietic stem cells, HCC-1+
5,681,559
5,677,136
SyStemix, Inc.
SyStemix, Inc.
researcher.
Over 1400 patents were identified. Each patent was evaluated and undifferentiated pluripotent stem cells obtained from a human blastocyst,
Sterne, Kessler, Goldstein & Fox P.L.L.C. classified as claiming (1) embryonic stem cells and embryonic stem proliferating in a growth environment containing an extracellular matrix and
Hematopoietic progenitor cells
CD34+, galactose-specific lectin+ 5,858,782 University of Michigan
cell preparations, (2) methods for isolating stem cells, (3) tissue a medium conditioned as described in the method claim. It may be possible Hematopoietic stem cells (quiescent), CD34+ 5,807,686 University of Minnesota; Rhone-Poulenc
About the Authors
specific stem cells, (4) genetically engineered stem cells and methods to avoid infringing this patent by not cultivating the stem cells free of feeder Rorer Pharmaceuticals What Royalty Payments Will Be Due?
of making, (5) methods of culturing and expanding stem cells, (6) cells, or by not using an extracellular matrix or conditioned medium as Keratinocyte stem cells 6,485,971 Peter MacCallum Cancer Institute
Robert W. Esmond, J.D., Ph.D., is a director and Robert A. Schwartzman, Ph.D., is methods of differentiating stem cells, and (7) methods of making specified in the claims. This patent will expire in 2021. Liver stem cells 6,129,911 Rhode Island Hospital, A Lifespan Partner
Do not express OC2 6,872,389 It is very possible that the commercial use of stem cell technology will
a patent agent at Sterne, Kessler, Goldstein & Fox P.L.L.C. The content of this article tissue in vitro or in vivo with stem cells as well as implants and require payments to multiple parties including:
Lymphohematopoietic progenitor stem cells;
reflects the present thoughts of the authors and should not be attributed to the firm prosthetics. The most important patents that may dominate the Geron also owns U.S. Pat. 6,800,480 which claims a composition My10– 5,256,560 University of Saskatchewan
or any of its former, current or future clients. Furthermore, this article is not an therapeutic use of stem cells will be discussed briefly. comprising undifferentiated human embryonic stem cells proliferating on an Mesenchymal stem cells; CD45+ 6,387,367 Osiris Therapeutics, Inc.
• Owners of patents on isolated stem cells and methods for their isolation.
opinion and is not an admission as to the scope, validity, enforceability or extracellular matrix and free from feeder cells. This patent may be avoided Mesenchymal stem cells 5,486,359 Osiris Therapeutics, Inc. • Owners of patents that claim methods of cultivating stem cells.
infringement of any of the patents mentioned herein. by cultivating the stem cells in the presence of feeder cells or in the absence Mesenchymal stem cells 5,827,735 MorphoGen Pharmaceuticals, Inc. • Owners of patents that claim methods for proliferating stem cells.
of extracellular matrix. This patent will expire in 2018. Mesenchymal stem cells 5,908,782 Osiris Therapeutics, Inc. • Owners of patents that claim methods of differentiating stem cells.
Pluripotent Mullerian duct-derived • Owners of patents that claim isolated, differentiated stem cells.
Patents That May Dominate the Geron also owns U.S. Pat. 6,642,048 which claims a method for epithelial cells 6,416,999 Raven Biotechnologies, Inc. • Owners of patents that claim genetically modified stem cells.
Abstract proliferating embryonic stem cells in a culture medium conditioned by Myeloid progenitor cells; c-kithi, IL-7Rα– 6,465,247 Stanford University • Owners of patents that claim the therapeutic method being
Use of Stem Cells culture of a non-malignant human cell line that proliferates in culture for at
Myeloid progenitor cells; Thy-1–, IL-7Rα–
Neural progenitor cells
6,761,883
5,753,505
Stanford University
Emory University
commercialized.
The patent landscape is already littered with a large number least 60 days. This patent may be avoided by not culturing stem cells in Neural stem cells 5,851,832 Neurospheres, Ltd.
• Owners of patents that claim specialized methods for administering the
of granted U.S. patents relating to stem cells. There are a Four companies/institutions have patents and patent applications that claim such a conditioned medium. This patent expires in 2021. stem cells.
Neuronal progenitor cells 6,251,669 Emory University
embryonic stem cells and methods for their isolation. Wisconsin Alumni • And, if the therapy was developed with California state money, the state of
number of broad patents owned by a handful of U.S. Research Foundation’s (WARF) U.S. Patent No. 5,843,780 claims a purified
Neuronal progenitor cells that do not express
companies and institutions that may dominate the growing Amrad Corporation Limited owns U.S. Pat. 5,166,065 which claims a a Hu protein 6,852,532 University of Utah Research Foundation California as well.
preparation of primate embryonic stem cells which (1) is capable of method for the isolation of embryonic stem cells from mammalian Lineage-restricted neuronal precursor cells;
and use of stem cells. Other patents cover more limited stem proliferating for over one year, (ii) maintains a karyotype in which all of the E-NCAM+ 6,734,015 University of Utah Research Foundation Such royalty stacking may make the therapeutic use of stem cells
cell technology, including particular uses of stem cells and embryos comprising deriving and maintaining the embryos in a culture prohibitively expensive.
chromosomes characteristic of primates are present and not noticeably medium comprising recombinant leukemia inhibitory factor. This patent
Central nervous system neural stem cells 5,968,829 Cytotherapeutics, Inc.
tissue specific stem cells. Anyone who wishes to develop stem altered through prolonged culture, (iii) maintains the potential to may be avoided by cultivating the stem cells in the absence of
Neuronal progenitor cells 6,812,027 Cornell Research Foundation, Inc.
cells for therapeutic purposes must be concerned about differentiate into derivatives of endoderm, mesoderm, and ectoderm tissues Central nervous system neuron-restricted
whether licenses to these patents will be necessary or even throughout the culture, and (iv) will not differentiate when cultured on a
recombinant leukemia inhibitory factor. This patent will expire in 2009.
Since any therapeutic methods employing embryonic stem cells will
precursor cells
Ventral mesencephalon neuron progenitor cells
6,787,353
5,411,883
University of Utah Research Foundation
Somatix Therapy Corp.
Is a Patent Pool the Answer?
available. Where there are multiple patents that relate to a fibroblast feeder layer. The ‘780 patent also claims methods for isolation of likely not come to market until well after 2009, it is unlikely that this Neural crest stem cells 5,589,376 California Institute of Technology
a primate embryonic stem cell line by (a) isolating a primate blastocyst, (b) A patent pool is an “agreement of two or more owners of different items of
particular stem cell therapy, royalty stacking may be patent will impede the commercialization of embryonic stem cells. Neutrophil precursor cells 5,955,357 Nexell Therapeutics Inc.
intellectual property to license one another and/or third parties.”2 Thus, a
necessary. Finally, a proposal to set up a patent pool for stem isolating cells from the inner mass of the blastocyst, (c) plating the inner cell Pancreatic progenitor cells 6,436,704 Raven Biotechnologies, Inc.
mass on embryonic fibroblasts, (d) dissociating the mass into dissociated Pancreatic islet progenitor cells; Express ErbB2 6,753,153 Scripps Research Institute
patent pool for stem cell patents could be a one stop shop for all patent rights
cell patents will be discussed. The Johns Hopkins University owns U.S. Pat. 6,090,622 which claims necessary to commercialize a therapy. Of course, all of the needed patent
cells, (e) replating the dissociated cells on embryonic feeder cells, (f) human pluripotential embryonic germ cells. Hopkins also owns U.S. Pat. Pluripotent cells 5,914,268 National Jewish Center for Immunology &
isolating colonies with compact morphologies and cells with high nucleus to Respiratory Medicine owners would have to agree to be part of the pool.
6,562,619 which claims a method for producing a differentiated cell Peripheral blood progenitor cells 5,541,103 Klinikum der Albert-Ludwigs-Universitat
cytoplasm ratios and prominent nucleoli, and culturing the cells of selected population from human embryonic germ cells. These patents will expire Freiburg
While some patent pools may be considered anti-competitive and
colonies. WARF’s U.S. Pat. 6,200,806 claims a purified preparation of in 2017. Renal stem cells 6,410,320 University of Michigan objectionable, the U.S. government has published guidelines that can be used
human embryonic stem cells and a method of isolation thereof similar to Renal stem cells 5,458,588 General Hospital Corporation to determine when a patent pool is pro-competitive and probably acceptable.
Strategists and Advisors specializing in the protection, transfer, that claimed in the ‘780 patent. These patents will expire in 2015. Tufts University researchers have reportedly isolated cells from bone Retinal stem cells 6,117,675 HSC Research and Development Limited The factors which suggest that a pool is pro-competitive include whether it:
Partnership
and enforcement of Intellectual Property Rights. marrow that have many of the hallmarks of embryonic stem cells. Tufts • Integrates complementary technologies.
WARF also owns related U.S. Published Application 2003/0008392. has reportedly filed a patent application to protect their discoveries.
Skeletal progenitor cells 6,517,872 Yada Research and Development Co., Ltd.
Ramdt University • Clears blocking positions.
However, since the claims of this patent may well change substantially by However, no published applications were identified by our search on the Stem cells; FGFR+, not ES cells 6,767,737 New York University • Reduces transaction costs.
the time it issues as a patent, if it ever does issue, the claims will not be USPTO database. Stem cells which give rise to blood cells; • Avoids costly infringement litigation.
discussed herein. A discussion of what claims might issue from pending CD34–, MHC-I–, MHC-II– 5,744,347 Ohio University Edison Biotechnology Institute • Promotes the dissemination of the technology.
U.S. applications is beyond the scope of this poster. T lineage progenitor cells;
CD8int, CD4int, c-kithi, high bcl-2, There are other considerations as well that go beyond the scope of this poster.
Vanderbilt University owns U.S. Pat. 5,453,357 which claims a composition CD8lo, CD4lo, c-kithi, high bcl-2 5,821,108 Stanford University However, the establishment of a patent pool for stem cells would be a
comprising (a) pluripotential embryonic stem cells and (b) fibroblast growth welcome development for anyone developing a stem cell therapeutic method.
factor, leukemia inhibitory factor, membrane associated steel factor and Tissue Specific Stem Cell Patents T lymphocyte precursor cells;
CD34+, CD7+, Leu 8+ 5,622,853 Becton Dickinson and Co.
soluble steel factor. Also claimed is a method of making a pluripotential
stem cell comprising administering a growth enhancing amount of basic Forty eight patents were identified that claim various tissue specific stem
fibroblast growth factor, leukemia inhibitory factor, membrane associated cells. The large majority of such patents are directed to hematopoietic stem
References
Summary
steel factor, and soluble steel factor to embryonic ectoderm cells under cell cells. Other types of stem cells claimed in these patents include adipose-
growth conditions. This patent will expire in 2012. Vanderbilt’s U.S. Pat. derived, dorsal root ganglion, epithelium, keritinocyte, liver, mesenchymal, 1 Waldman, M., “Licensing fees slow advance of stem cells,” Nature 435:272–273 (May, 2005). The patent landscape is littered with issued patents that may affect the ability
5,690,926 claims isolated non-murine mammalian pluripotential cells mullerian duct-derived, myeloid, neural, pancreatic islet, renal, retinal, and 2 Antitrust Guidelines for the Licensing on intellectual Property,” issued by the U.S. Department of to practice therapeutic methods with stem cells. Careful review of the patent
which, among other things, are derived from a primordial germ cell by skeletal stem cells. These patents include those in the following table. Justice and the Federal Trade Commission, April 6, 1995. literature will be essential at the beginning of any research project.